ロード中...
Cdk5 knocking out mediated by CRISPR-Cas9 genome editing for PD-L1 attenuation and enhanced antitumor immunity
Blocking the programmed death-ligand 1 (PD-L1) on tumor cells with monoclonal antibody therapy has emerged as powerful weapon in cancer immunotherapy. However, only a minority of patients presented immune responses in clinical trials. To develop an alternative treatment method based on immune checkp...
保存先:
| 出版年: | Acta Pharm Sin B |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Elsevier
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7016277/ https://ncbi.nlm.nih.gov/pubmed/32082979 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.apsb.2019.07.004 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|